Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1951 3
1952 3
1953 5
1954 6
1955 5
1956 6
1957 2
1958 8
1959 28
1960 34
1961 31
1962 27
1963 4
1964 12
1965 79
1966 228
1967 373
1968 422
1969 453
1970 555
1971 640
1972 597
1973 639
1974 714
1975 637
1976 596
1977 709
1978 686
1979 726
1980 858
1981 908
1982 1029
1983 1123
1984 1279
1985 1394
1986 1334
1987 1441
1988 1557
1989 1910
1990 1936
1991 1864
1992 1941
1993 2122
1994 2258
1995 2385
1996 2407
1997 2547
1998 2685
1999 2803
2000 3105
2001 3434
2002 3671
2003 3989
2004 4186
2005 4541
2006 5008
2007 5534
2008 6108
2009 6327
2010 7162
2011 7697
2012 8274
2013 8620
2014 9111
2015 9325
2016 8663
2017 8534
2018 8360
2019 4467
2020 102
Text availability
Article attribute
Article type
Publication date

Search Results

156,426 results
Results by year
Filters applied: . Clear all
Page 1
Hepatocellular carcinoma: From diagnosis to treatment
Grandhi MS, et al. Surg Oncol 2016 - Review. PMID 27312032
While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional therapy and sorafenib are beneficial in those with more advanced disease or those who are not surgical candidates. At times, the integration of both surgical and locoregional therapy may be necessary. Hence, hepatocellular carcinoma requires a multidisciplinary approach to determine the most appropriate treatment as well as the timing of various treatments for optimal outcomes....
While surgical resection and transplantation are the cornerstone of therapy in early-stage hepatocellular carcinoma, locoregional …
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Mazur PK, et al. Nat Med 2015. PMID 26390243 Free PMC article.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and shows resistance to any therapeutic strategy used. ...Finally, using a CRISPR-Cas9-based method for gene editing directly in the mouse adult pancreas, we show that de-repression of p57 (also known as KIP2 or CDKN1C) upon combined BET and HDAC inhibition is required for the induction of combination therapy-induced cell death in PDAC. ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers and shows resistance to any therapeutic strategy used …
Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.
Cloyd JM, et al. J Gastrointest Surg 2017. PMID 27778257
BACKGROUND: The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal adenocarcinoma (PDAC) prior to pancreatoduodenectomy (PD). ...Further improvements in patient outcomes will likely require disruptive advances in systemic therapy....
BACKGROUND: The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patien …
Perioperative Management of Hilar Cholangiocarcinoma
Poruk KE, et al. J Gastrointest Surg 2015 - Review. PMID 26022776 Free PMC article.
As a result of recent efforts, new methods of management have been identified for these patients, including preoperative portal vein embolism and biliary drainage, neoadjuvant chemotherapy with subsequent transplantation, and chemoradiation therapy. CONCLUSION: Current management of hilar cholangiocarcinoma depends on extent of the tumor at presentation and includes surgical resection, liver transplantation, portal vein embolization, and chemoradiation therapy. ...
As a result of recent efforts, new methods of management have been identified for these patients, including preoperative portal vein embolis …
Adjuvant chemotherapy in early breast cancer
Ejlertsen B. Dan Med J 2016 - Review. PMID 27127018
With long-term follow-up, the DBCG 77B trial demonstrates that oral single-agent cyclophosphamide significantly reduces the risk of recurrence and mortality as compared with no systemic therapy in pre-menopausal patients with high-risk early breast cancer. ...However, according to a large cohort study from DBCG, chemotherapy can safely be withheld in one fourth of postmenopausal patients who will be without excess mortality following sufficient adjuvant endocrine therapy for ER positive breast cancer. ...
With long-term follow-up, the DBCG 77B trial demonstrates that oral single-agent cyclophosphamide significantly reduces the risk of recurren …
Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF, et al. Rev Endocr Metab Disord 2018 - Review. PMID 29464446
There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional therapies as well as systemic therapeutic options including peptide receptor radionuclide therapy, cytotoxic therapy, and molecularly targeted therapies. ...Supportive therapy plays a key role in NET treatment. Supportive therapy includes debulking surgery and interventional radiologic techniques to reduce tumour bulk or load, as well as systemic medical treatment options to manage or prevent hypersecretion syndromes and treatment-related side effects. ...
There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional ther …
[Palliative therapy concepts for pancreatic carcinoma].
Brunner M, et al. Chirurg 2018. PMID 30094706 German.
The majority of patients with ductal pancreatic adenocarcinoma are already in a locally advanced or metastatic stage at the time of diagnosis and require palliative therapy. ...In the presence of tumor-related pain, pain therapy according to the World Health Organization (WHO) scheme or a truncus coeliacus blockade, in cachexia a nutritional therapy and in thromboembolic events an anticoagulant therapy are used. ...
The majority of patients with ductal pancreatic adenocarcinoma are already in a locally advanced or metastatic stage at the time of d …
Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.
Tsuchiya N, et al. Anticancer Res 2019. PMID 31366541
BACKGROUND/AIM: To identify risk factors of early recurrence after neoadjuvant chemoradiation therapy (NACRT) and curative pancreatectomy in patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). ...
BACKGROUND/AIM: To identify risk factors of early recurrence after neoadjuvant chemoradiation therapy (NACRT) and curative pancreatec …
156,426 results
Jump to page
Feedback